Navigation Links
Results of the BRIDGE trial reported at TCT 2011
Date:11/9/2011

SAN FRANCISCO, CA November 9, 2011 Data from the BRIDGE clinical trial demonstrate that intravenous use of the drug cangrelor was effective at maintaining platelet inhibition in patients on thienopyridines who required bypass surgery. Trial results were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

Thienopyridines are anti-platelet medications that work to prevent blood clotting and improve circulation. Though they are among the most widely prescribed medications, their use can be complicated by the unanticipated need for surgery. Despite increased risk of thrombosis, guidelines recommend discontinuing thienopyridines 5 7 days prior to surgery to minimize bleeding.

In the BRIDGE trial, researchers sought to determine whether the investigational drug cangrelor could be used as a "bridge" between discontinuing thienopyridines and surgery.

BRIDGE is a prospective, randomized double-blind, placebo-controlled, multicenter trial in 210 patients with acute coronary syndrome (ACS) or treated with a coronary stent on a thienopyridine awaiting coronary artery bypass grafting (CABG) to receive either cangrelor or placebo after an initial open-label, dose-finding phase. After thienopyridines were stopped, patients were administered cangrelor or a placebo for at least 48 hours, which was then discontinued 1 6 hours prior to surgery.

The primary efficacy endpoint of the trial was platelet reactivity (measured in P2Y12 Reaction Units [PRU]), assessed daily with the VerifyNowTM P2Y12 assay. The main safety endpoint was excessive CABG-related bleeding.

The dose of cangrelor determined in the open-label stage was 0.75 g/kg/min. In the randomized phase, a greater proportion of patients treated with cangrelor had low levels of platelet reactivity throughout the entire treatment period compared with placebo (primary en
'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Page: 1 2

Related medicine news :

1. First results of Angiomax (bivalirudin) vs. heparin in transcatheter aortic valve interventions
2. Osteoarthritis results from inflammatory processes, not just wear and tear, Stanford study suggests
3. E-counselling shows dramatic results in lowering blood pressure
4. Less Frequent Mammograms May Lower False-Positive Results
5. Mayo Clinic wins grant to study ethics of sharing genetic test results with relatives
6. TGen/Virginia G. Piper Cancer Center publish results of new drug for pancreatic cancer patients
7. Virtual fly-through bronchoscopy yields real results
8. Mixed Results Seen With Off-Label Use of Antipsychotics
9. Company stock prices before public announcements of oncology trial results
10. Check Plastic Surgeons Credentials or Risk Tragic Results, Experts Warn
11. Parents anxiety about newborn screening results does not lead to increased health care use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... CA (PRWEB) July 28, 2014 With ... us, it is welcome news that a fire ... than current protection is under development by SunSeeker Enterprises, ... NASA to protect spacecraft from the extreme heat of ... to both firefighters and homes. , “Our firefighters routinely ...
(Date:7/28/2014)... 2014 The report “Industrial Enzymes ... & Beverages, Cleaning Agents, Bio-Fuel, Animal Feed), & ... defines and segments the global industrial enzymes market ... for industrial enzymes. It also identifies driving and ... with analysis of trends, opportunities, burning issues, winning ...
(Date:7/28/2014)... from The University of Texas Health Science Center at San ... a combination of pills that cures 9 of 10 hepatitis ... simeprevir, with or without ribavirin, cured 93 percent of patients ... to the study published today in The Lancet . ... , Eric Lawitz, M.D., clinical professor in the School of ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Recent research ... desk all day for years can lead to a ... cardiovascular disease. But using a standing desk, or an ... pain, often driving office workers back to a seated ... are designed to alleviate this leg pain and ...
(Date:7/28/2014)... MONDAY, July 28, 2014 (HealthDay News) -- A ... stiffness in older people may increase the risk ... suggests. A British study found that patients ... vascular disease -- conditions that affect the blood ... factors of patients with polymyalgia rheumatica to reduce ...
Breaking Medicine News(10 mins):Health News:Revolutionary Fire Blanket Offers Over 200 Percent More Fire Protection to Firefighters and Homes 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4Health News:New pill regimens published in The Lancet cure hardest-to-treat hepatitis C patients 2Health News:New Standing Desk Anti-fatigue Mats from Martinson-Nicholls Reduce Leg Fatigue and Discomfort Working at Standing and Sit-to-Stand Desks 2Health News:Inflammatory Muscle Disorder May Raise Risk for Heart Attack, Stroke 2
... dating has not only shed its stigma, it has ... other than meeting through friends, according to a new ... The digital revolution in romance is a boon ... potential partners, reports the team of psychological scientists who ...
... , FRIDAY, Feb. 3 (HealthDay News) -- ,Extended synaptic development ... new study suggests. During the first few years of ... information and experiences from the environment in a way that ... This is due to extended synaptic development, according to the ...
... been mapped with unprecedented accuracy in the bloodstream of ... brand new approach, in an attempt to assess and ... through the body, and solve the problem of predicting ... to a previous generation of systems, the researchers state ...
... aged 70 and over will increase by 40% in ... over will more than double1. Health authorities and the ... of people suffering costly and debilitating age-related chronic diseases ... dementia. The significant increase in the numbers of people ...
... (February 1, 2012) Rates of diabetes vary widely across ... by Dr. Longjian Liu of Drexel University,s School of ... diabetes now live in developing countries. Liu,s study found ... in developing countries, and that one in 10 diagnosed ...
... , THURSDAY, Feb. 2 (HealthDay News) -- Sometimes, there,s nothing ... that where the itch resides is key to ... understanding of itch and might even help folks battling itchy ... professor of dermatology at Wake Forest Baptist Medical Center in ...
Cached Medicine News:Health News:Online dating research shows cupid's arrow is turning digital 2Health News:Online dating research shows cupid's arrow is turning digital 3Health News:Why Human Brains Are Smarter Than Chimp Brains 2Health News:New technology to tackle treatment-resistant cancers 2Health News:New study to assess 3 simple, cost-effective strategies to promote healthy aging 2Health News:Diabetes rates vary widely in developing countries, 1 in 10 cases untreated 2Health News:Pleasure in Scratching an Itch May Depend on Location 2
(Date:7/28/2014)... 28, 2014  VigeneTech, Inc, in collaboration with ... Data Analysis Software, an OEM software solution for ... develops and offers varieties of bead-based multi-analyte immunoassay ... support of VigeneTech,s data analysis software, FCS data ... easily reported LEGENDplex™ software is ...
(Date:7/28/2014)... 2014 Research and Markets  has announced the ... report to their offering. ... leads to inflammation and pain in the human body,s joints ... it causes inflammation of the tissues that surround the joints ... of RA begin slowly, usually just mild pain around the ...
(Date:7/28/2014)... , July 28, 2014  Syneron Medical Ltd. (NASDAQ: ... company, announced today that its new PicoWay® device has ... types and colors and pigmented lesions on any skin ... device, with 532nm and 1064nm wavelengths, which utilizes Syneron,s ... using pulses which are trillionths of a second, known ...
Breaking Medicine Technology:VigeneTech Releases New Powerful Software for Flow Cytometry Data Analysis 2Global Rheumatoid Arthritis Drugs Market 2014-2018 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4
... and Only Approved Platelet Producer in Europe Represents ... Switzerland, Feb. 6 Amgen (Nasdaq: ... (EC) has granted marketing authorisation for Nplate(R) (romiplostim) ... (idiopathic) thrombocytopenic purpura (ITP) patients who are refractory ...
... CAMBRIDGE, Mass. and LONDON, Feb. 6 Idenix Pharmaceuticals, ... today announced the execution of a license agreement granting ... a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) in Phase ... treatment of HIV/AIDS. New NNRTIs are needed to ...
Cached Medicine Technology:Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 2Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 3Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 4Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 5Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 6Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 7Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 8Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV 2Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV 3Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV 4Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV 5
... cervical stabilization from neutral to ... widening under occiput when collar ... fasterner.,Exo-Static™ Collar with Chin Piece ... neutral position and restricts lateral ...
... Padding&trade is perfect for use for lightweight ... materials or used to line braces, prosthetics, ... against shock and vibration and conforms to ... and chaffing. It is a 2mm thick ...
... support and stabilization for muscles and ligaments ... pain and discomfort. Strong elastic abdominal ... for varying degrees of compression. Two ... for extra-firm support. Tapered in front ...
... Designed with patient need and comfort ... Appliance) family of products effectively address ... The Chairback frame attachment provides optimal ... (LSO) provides superior support for patient ...
Medicine Products: